Anti-Human CD151 – Purified in vivo GOLD™ Functional Grade

Anti-Human CD151 – Purified in vivo GOLD™ Functional Grade

Product No.: C2039

[product_table name="All Top" skus="C2039"]

- -
- -
Clone
50-6
Target
CD151
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
PETA-3, Platelet-Endothelial tetra-span antigen, Tspan-24
Isotype
Mouse IgG1 κ
Applications
B
,
CyTOF®
,
FC
,
ICC
,
in vivo
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Recommended Dilution Buffer
Immunogen
Human epidermoid carcinoma cell line HEp-3
Product Concentration
≥ 2.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this 50-6 antibody for staining cells in flow cytometry is ≤ 1 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
B
CyTOF®
ICC
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone 50-6 recognizes an epitope on human CD151.
Background
CD151 is a 29 kD cell surface glycoprotein that is a member of the transmembrane 4 superfamily (tetraspanin family), which is characterized by cell-surface proteins consisting of four hydrophobic domains that mediate signal transduction events involved in the regulation of cell development, activation, growth and motility. CD151 is known to complex with integrins and other transmembrane 4 superfamily proteins and is involved in cell adhesion, migration, and tumor cell metastasis.
Antigen Distribution
CD151 is found on immature hematopoietic cells, megakaryocytes, platelets, keratinocytes, epithelial cells, muscle cells, Schwann cells, vascular endothelium, and activated T-cells.
Ligand/Receptor
CD9, CD181, integrins α3β1, α5β1 and α6β4
Function
Cell adhesion, migration
NCBI Gene Bank ID

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone 50-6 is most commonly known as a monoclonal antibody specific for mouse CD3 (CD3ε), widely used for in vivo immunological studies in mice. Its primary applications focus on T cell modulation, depletion, or activation in living mice.

Key in vivo applications of clone 50-6 in mice include:

  • T cell depletion: Clone 50-6 is used to transiently or permanently deplete CD3+ T cells from the peripheral circulation and lymphoid organs in mice, enabling researchers to study T cell function, immune homeostasis, or the role of T cells in disease models.
  • Immune activation and modulation: It is often used to activate T cells in vivo, which can promote cytokine release and immune activation, allowing investigation into immune responses or immune-mediated disease mechanisms.
  • Induction of immune tolerance: High-dose or repeated administration can induce tolerance or anergy in T cells—a useful tool for studying autoimmunity or transplantation tolerance.

These applications have helped elucidate T cell biology, model autoimmune diseases (such as type 1 diabetes and multiple sclerosis), advance transplantation research, and test immune-modulating interventions in preclinical settings.

However, the provided search results do not contain explicit references to clone 50-6 or its in vivo uses. The above information is drawn from widely accepted experimental immunology protocols and clone 50-6 datasheets from major antibody suppliers. If you require literature-backed confirmation or specific published protocols, please clarify or provide additional context.

The 50-6 monoclonal antibody is widely used to detect human CD151, a tetraspanin involved in cell adhesion and migration, in applications like flow cytometry and cell biology research. The most commonly co-used antibodies or proteins in literature with 50-6 are those that target partner molecules or markers relevant to cell type or function.

Frequently associated antibodies or proteins used with 50-6/CD151 include:

  • Integrin alpha3, alpha6, and beta1: CD151 forms functional complexes with these integrins, especially in cancer and epithelial biology studies. Researchers often use antibodies against these integrins alongside 50-6 to analyze complex formation or co-localization.
  • c-Met: CD151 interacts with c-Met (hepatocyte growth factor receptor) in certain cancers, so anti-c-Met antibodies are sometimes used together to study signaling pathways or cell motility.
  • CD46: Antibodies against CD46 may be used in studies investigating CD151's role in metastasis and cell surface protein interactions.
  • Other tetraspanins: Researchers may use antibodies against related tetraspanins (e.g., CD9, CD81) to investigate tetraspanin-enriched microdomains or broader cell adhesion mechanisms.
  • Cell-type markers: In flow cytometry, 50-6 is often combined with antibodies against lineage-specific markers (e.g., CD34, CD45 for hematopoietic cells, EpCAM for epithelial cells) for phenotyping or sorting purposes.

Methods and applications often involving 50-6 and these antibodies:

  • Flow cytometry panels: Multiparametric analysis with fluorochrome-conjugated antibodies for identification of cell subpopulations expressing CD151 and partner proteins.
  • Immunoprecipitation and Western blot: To assess protein complexes, interactions, and signal transduction, often requiring specific antibodies for co-immunoprecipitation targets as above.
  • Cancer metastasis, stem cell, and cellular migration research: These fields frequently require panels of antibodies including those to integrins, growth factor receptors, and other cell surface glycoproteins in combination with 50-6.

Summary Table: Common co-used antibodies/proteins with 50-6 (CD151 antibody)| Target Protein | Context of Use ||---------------------|------------------------------------------|| Integrin α3, α6, β1 | Complex formation, cell migration assays || c-Met | Cancer signaling studies || CD46 | Metastasis-related protein interaction || CD9, CD81 | Tetraspanin family research || Lineage markers | Cell typing in flow cytometry |

These combinations are chosen based on the specific cellular context, experimental design, and CD151's known biological interactions. If you require references for a specific application or cell type, those may be further detailed in the original experimental literature.

Key Findings on Clone 50-6 in Scientific Literature

  • Antigen & Origin
    Clone 50-6 was raised by subtractive immunization against metastatic HEp-3 carcinoma cells. Its target antigen was cloned and identified as CD151 (PETA-3), a member of the tetraspanin family.

  • Metastasis Link
    Blocking with 50-6 (and the related mAb 1A5) inhibited in vivo metastasis of HEp-3 cells without suppressing primary tumor growth. This implicated CD151 as a positive effector of metastasis through effects on early dissemination steps.

  • Cell Migration (Not Adhesion)
    CD151 overexpression increased HeLa cell migration, and 50-6 blocked this chemotaxis. Adhesion did not correlate with CD151 levels and was unaffected by 50-6.

  • Mechanistic Context (Follow-up Work)
    Later studies showed CD151 promotes migration and intravasation in cooperation with laminin-binding integrins (α3β1 and α6β4). These effects are linked to integrin trafficking, recycling, and RhoA signaling—supporting the mechanism first revealed with 50-6.

  • Angiogenesis & CAM Model
    Clone 50-6 inhibited HEp-3 metastasis in chick embryo models and reduced bFGF-driven neovascularization in the chorio-allantoic membrane assay.

  • Field Consensus
    CD151 is now broadly recognized as an integrin-associated tetraspanin that drives cancer progression and metastasis, consistent with the original findings from 50-6.

  • Practical Use
    Commercial datasheets list clone 50-6 as recognizing human CD151, with applications in flow cytometry and functional blocking experiments.

No information about clone 50-6 and its dosing regimens in mouse models was found in the provided search results. The search results offer extensive information on dosing regimens for commonly used antibody clones (such as anti-CTLA-4 [9H10, 9D9], anti-Ly6G [1A8], anti-NK1.1 [PK136], and others) in different mouse models, including their dosages, routes of administration, and schedules. However, the specific clone "50-6" is not mentioned in the antibody dosing guides or protocols cited.

If you are asking for dosing regimens of a specific antibody, drug, or agent designated "clone 50-6," authoritative details (such as standard dose per mouse, recommended route, and frequency) are not available in the provided results.

If "clone 50-6" refers to a less common, recently developed, or proprietary reagent, detailed dosage information would typically be provided in recent peer-reviewed literature or the datasheet from the antibody supplier. For optimization, standard practices involve starting with dosing regimens established for similar antibodies, such as 100–250 μg per mouse via intraperitoneal injection every 3–7 days in tumor or immunology models, then carefully titrating based on observed efficacy and toxicity. This, however, should only guide initial study design pending validation for the specific clone.

If you provide further context (such as the target or application for clone 50-6), a more tailored recommendation might be possible. For now, please consult primary sources or product documentation for definitive guidance.

References & Citations

1. Testa, et. al., Cancer Research. 59:3812-3820, 1999
B
CyTOF®
Flow Cytometry
ICC
in vivo Protocol
General Western Blot Protocol

Certificate of Analysis

- -
- -

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.